054670 — Daehan New Pharm Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩113bn
- KR₩126bn
- KR₩204bn
- 75
- 64
- 15
- 51
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 134,097 | 149,293 | 166,586 | 197,957 | 204,223 |
Cost of Revenue | |||||
Gross Profit | 72,350 | 76,340 | 83,969 | 90,546 | 93,983 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 113,399 | 158,782 | 141,467 | 161,475 | 185,413 |
Operating Profit | 20,698 | -9,489 | 25,119 | 36,482 | 18,809 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 19,764 | -12,671 | 23,580 | 34,520 | 20,683 |
Provision for Income Taxes | |||||
Net Income After Taxes | 15,239 | -10,120 | 15,694 | 24,317 | 12,542 |
Net Income Before Extraordinary Items | |||||
Net Income | 15,239 | -10,120 | 15,694 | 24,317 | 12,542 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 15,239 | -10,120 | 15,694 | 24,317 | 12,542 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1,086 | 858 | 1,193 | 1,285 | 894 |
Dividends per Share |